CoChat

Tumor vascular infarction: prospects and challenges

Jahanban-Esfahlan, Rana, Seidi, Khaled, Zarghami, Nosratollah · 2017 · International Journal of Hematology

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Formation of fibrin clots may be sufficient to occlude the blood vessels that feed tumor cells, contributing to massive ischemia, vascular infarction, and the subsequent necrosis and apoptosis of neoplastic cells. This approach called as tumor vascular infarction was pioneered by Huang et al. (Science 275:547-550, 1997). Since then, different vascular targeting moieties were linked to a truncated form of human tissue factor (tTF), to generate coaguligands with selective thrombotic activities on tumor neovasculature. In contrast to the wide clinical application of angiogenesis inhibitors and tumor vascular disrupting agents, tTF-NGR is the only example of clinically tested coaguligands. Notably, among these three tumor vascular targeting approaches, tumor vascular infarction is the only modality manifesting long-term curative potential in mice. Translation of this worthy approach has been limited, as induction of thrombosis by TF fusion proteins is leaky. In this review, we describe the clinical significance of tumor vascular infarction, highlight its advantages and disadvantages, and propose a novel strategy for expediting its translation to clinical settings.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12185-016-2171-3

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Cited by

See all 88

Metadata

Authors
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N.
Affiliations
Tabriz University of Medical Sciences (IR)
Corresponding author
Zarghami, Nosratollah
Venue
International Journal of Hematology
Published
2017-01-02
Volume
105
Issue
3
Pages
244-256
ISSN
  • 0925-5710 (ISSN-L)
  • 1865-3774
OpenAlex
W2567676221
Cited by
88
References
64
Citations by year
2026: 5 · 2025: 7 · 2024: 10 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 5
FWCI
0.51
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Hematology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Iran National Science Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
tumor neovasculature, tissue factor, thrombosis, fibrin clot, tumor ischemia, tumor necrosis, vascular targeting, angiogenesis inhibitors, clinical translation
MeSH terms
Animals, Humans, Neoplasms, Neovascularization, Pathologic, Thromboplastin, Thrombosis, Angiogenesis Inhibitors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor vascular infarction: prospects and challenges. https://app.cochat.ai/papers/10.1007/s12185-016-2171-3
The paper
Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N. (2017). Tumor vascular infarction: prospects and challenges. International Journal of Hematology. https://doi.org/10.1007/s12185-016-2171-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.